Janux Therapeutics has entered into a global collaboration and exclusive licensing agreement with Bristol Myers Squibb to develop a novel cancer therapy for solid tumours. The partnership is valued at up to USD eight hundred fifty million, including upfront payments and development, regulatory, and commercial milestones.
Janux Therapeutics | 23/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy